Tumour-agnostic drug development is revolutionising precision oncology
While the field is rapidly evolving, regulatory shifts and greater access to tumour profiling are now needed to realise the full benefits for patients
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor
ctDNA and beyond to serve immunotherapy
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Next steps for research include personalising regimens and learning how to predict response and toxicity
Preventing the rise in obesity-related cancers in Asia
Long-term multisectoral preventive actions that take into account local requirements are needed
Translating cancer genome insights into practical clinical tools
Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions
Innovation is leading to a comprehensive ‘map’ of tumours
Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targets
How to bridge the gap between palliative care and oncology?
Evidence from well-designed clinical trials is key to promote greater acceptance and access to palliative care
Physical activity is beneficial for patients with cancer, but also challenging
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
Rising rates of cancer in young people: nature or nurture?
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest